SAN DIEGO, May 20, 2004 (BUSINESS WIRE) -- Pharmessen Scientific, Inc. (Other OTC: PASC.PK - News), a global nutraceutical and pharmaceutical research company focused on providing leading supplements and medications for better general health, announced today the opening of a new overseas office, located in Tokyo, Japan.
The new office will service existing demand for Pharmessen's products and identify additional business opportunities throughout Japan. Mr. Mitsuyuki Iwakata will serve as General Manager of Business Development at Pharmessen's Tokyo, Japan operations center.
The Tokyo office will serve as a hub for Pharmessen's distribution, marketing, and business development initiatives throughout Japan. "Japan represents a growing and strategic marketplace for our product offerings, and we feel confident in our ability to succeed in this region," commented Mr. George Macleod, Pharmessen's Chief Executive Officer. "We are also fortunate to bring on board such a talented individual as Mr. Mitsuyuki Iwakata and expect that his marketing and business development contributions will have an immediate impact."
Mr. George Macleod further commented, "This is an important step in Pharmessen's global expansion and presence. Over the next two years we will aggressively expand our nutraceutical and pharmaceutical products, inclusive of dietary supplements, performance enhancers, and natural compounds, into the Middle East, Europe and South America."
Pharmessen's Tokyo, Japan office is located at:
Kyodo Building (Minami-Aoyama) 5F
Minato-ku, Tokyo 107-0062
About Pharmessen Scientific, Inc.
Pharmessen Scientific, Inc. is a global nutraceutical and pharmaceutical company that was formed to research, develop, produce, and market pure herbal supplements and compounds. At the core of Pharmessen's business are its patented encapsulation technology and "water activation" delay processes, which in combination enable the company's products to benefit from enhanced and extended potency. Utilizing this proprietary blending formula, the company effectively combines herbal oil extracts from organically grown plants to create novel supplements and compounds. Pharmessen is presently developing new anti-microbial and biocide agents in order to improve the treatment of diseases caused by new and multi-resistant pathogens.
This release contains forward-looking statements with respect to the results of operations and business of Pharmessen Scientific, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995